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Purpose
Aim of this study was to assess whether specified
immune cells subsets at baseline could help identifying
patients with longer progression-free survival (PFS) in a
clinical trial of metastatic breast cancer patients receiv-
ing docetaxel±vaccine.
Methods
We applied flow-cytometer analysis of PBMCs harvested
before treatment from patients (n=43) enrolled in a small
randomized phase II study of docetaxel alone (n=20) or
in combination with PANVACTM-V (Vaccinia) and PAN-
VACTM-F (Fowlpox) encoding for the tumor-associated
antigens CEA and MUC-1, along with a TRIad of
COstimulatory Molecules (B7-1, ICAM-1, and LFA-3;
called TRICOM) (n=23). As criterion 1, we analyzed the
frequency standard immune subsets, i.e. CD4, CD8, NK,
Treg, MDSC, and their ratios. As criterion 2, we mea-
sured phenotypes indicating immune function, i.e. central
memory T lymphocytes, T cells expressing at ≥2 suppres-
sive markers among CTLA-4, PD1, TIM3, and 2B4,
CD49d- Tregs, lin- MDSCs, CD56brCD16- NK cells, and
their ratios. An immunoscore was generated based on
the analysis of tertiles. Log-Rank Kaplan Meier analysis
was applied to evaluate differences of PFS between
patients with low- and- high immunoscore.
Results
The predetermined immunoscore based on phenotypes
indicating immune function allowed discrimination
between patients with longer PFS vs. shorter PFS in vac-
cine plus docetaxel arm (p<0.001, HR=0.049) but not in
docetaxel alone arm (p=0.875; HR=0.926).
Conclusions
The calculation of an immunoscore based on a flow-cyt-
ometer screening of predetermined immune subsets
indicating immune function from PBMCs before treat-
ment could be a potential useful tool for the identifica-
tion of patients that can benefit from combination
immunotherapy.
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